Dr. Zhenping Zhu is currently the Chairman and CEO of Danson Pharmaceutical Technology (Shanghai) Co., LTD. He was president of Pharmaceutical Research and Development and Chief Scientific Officer of Sansheng Pharmaceutical. Prior to joining Our company in January 2017 He served as Executive Vice President, Global biopharmaceutical Research and Development and President, Kadmon China, at Kadmon Corporation from 2010 to 2016. Prior to joining Kadmon, Dr. Zhu served as Vice President, Global Head of Protein Science and Drug Design at Novartis from 2009 to 2010 where he was responsible for the exploration, design and selection of novel biologics for the treatment of various human diseases. Prior to joining Novartis, Dr. Zhu served as Vice President of Antibody Technology and Immunology for over 12 years at ImClone Systems, where he led teams responsible for the successful discovery and early development of several novel FDA-approved anti-tumor antibodies, including Cetuximab (Erbitux, Erbitux), ramucirumab(Cyramza), necitumumab(Portrazza) and olaratumab(Latruvo). Dr. Zhu is the patent inventor of Ramucirumab and necitumumab, and is one of the major contributors to Cetuximab and Olaratumab. He received his bachelor's degree in medicine from Jiangxi Medical College in 1985. He received his Master's degree in pharmacology from the Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College in 1988 and his doctor's degree in immunology and Pathology from Dalhousie University in Canada in 1993. From 1993 to 1996 Dr. Zhu worked as a postdoctoral fellow in antibody and protein engineering at Genentech. From 1996 to 2006, Dr. Zhu was a visiting professor at the Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College. Dr. Zhu has published over 190 peer-reviewed scientific papers as well as over 50 publications in the United States and The United States Patent inventor or co-inventor of international patents and patent applications.